• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    WHOOP Launches Clinician-Reviewed Advanced Labs, Unlocking a Comprehensive View of Human Health

    9/30/25 9:00:00 AM ET
    $DGX
    Medical Specialities
    Health Care
    Get the next $DGX alert in real time by email

    Over 350,000 members have joined the waitlist since May, underscoring the excitement for one product that can pair blood biomarkers with 24/7 wearable data

    WHOOP, the human performance company, today announced the launch of WHOOP Advanced Labs, a groundbreaking new feature that combines blood testing with continuous wearable data to deliver a complete picture of health. Members can upload past bloodwork results or schedule the company's curated Advanced Labs panel, which tests an extensive set of biomarkers.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250930178710/en/

    WHOOP Launches Clinician-Reviewed Advanced Labs, Unlocking a Comprehensive View of Human Health

    WHOOP Launches Clinician-Reviewed Advanced Labs, Unlocking a Comprehensive View of Human Health

    Since previewing the feature in May, more than 350,000 current WHOOP members have signed up for the waitlist, reflecting massive demand for deeper insights into human health. Starting today, members in the United States will begin gaining access, with a global rollout to follow. This announcement is the next step for WHOOP in its mission of adding one billion healthy years to people's lives.

    "WHOOP Advanced Labs bridges two worlds: lab diagnostics and 24/7 continuous monitoring," said Will Ahmed, Founder and CEO of WHOOP. "For the first time, our members can see how their blood biomarkers and daily behaviors connect in real time. This is all part of our path to becoming a health operating system that helps our members live better and longer."

    Expert Perspectives

    WHOOP developed this product in conjunction with the WHOOP Medical Advisory Board, made up of renowned doctors, researchers, and medical professionals, including Dr. Hazel Wallace, Dr. Robin Berzin, Dr. Eric Verdin and Dr. Dan Henderson.

    "Bloodwork can sometimes leave people with more questions than answers," said Dr. Hazel Wallace (MBBCh, BSc, MSc), nutritionist, author, and founder of The Food Medic. "WHOOP Advanced Labs helps bridge that gap by putting health insights directly into the hands of the individual, where habits can make a powerful difference."

    Speaking about the launch, endurance athlete, author, and podcaster Rich Roll said: "As someone who regularly gets bloodwork done, WHOOP Advanced Labs is revolutionary in helping people connect the reality of their health with themselves, and with their healthcare practitioners. To be able to see what's on the horizon, well in advance of a problem becoming too advanced that it's too late to deal with; I think that is fantastic."

    Proactive Health Made Personal with AI

    WHOOP Advanced Labs creates a continuous feedback loop where periodic blood tests inform daily coaching in real time. Core benefits of WHOOP Advanced Labs include:

    • Testing of the most-impactful biomarkers that affect your health
    • Clinician-reviewed results provide expert context and personalized recommendations
    • AI-powered coaching provides daily guidance and insights
    • Progress tracking shows how lifestyle adjustments influence biomarkers over time

    How WHOOP Advanced Labs Works

    WHOOP Advanced Labs gives members two powerful ways to bring these biomarkers into the WHOOP experience:

    1. Upload Any Pre-Existing Bloodwork

      Members can now upload results from any lab provider directly into the WHOOP app at no additional cost. This makes it easy to centralize all results, track long-term trends, and connect them with continuous WHOOP data on sleep, training, recovery, and lifestyle.



    2. Book Comprehensive Testing through the WHOOP app

      For an even deeper experience, members can subscribe to WHOOP Advanced Labs and schedule curated blood tests directly through the WHOOP app, powered by Quest Diagnostics (NYSE:DGX) across the United States. Results are automatically synced to the WHOOP app and reviewed by a clinician who provides expert context. Subscription options include: one test for $199, two tests per year for $349, or four tests per year for $599, with additional tests available at discounted rates. Tests are reviewed and ordered by a licensed healthcare provider.

    In both cases, WHOOP does what no traditional blood test can: connecting biomarker results with 24/7 physiological data to reveal how your habits and behaviors directly impact your health.

    Helping Unlock One Billion Healthy Years

    Earlier this year, WHOOP announced its long-term goal to add One Billion Healthy Years to people's lives as part of its mission to unlock human performance and healthspan. Healthspan refers to the number of years someone lives in good health, free from chronic disease, functional decline, and preventable limitations. Each week, WHOOP calculates the net change in its members' lives using the app's Healthspan feature, helping members understand how daily behaviors are adding or subtracting from their long-term healthspan. WHOOP Advanced Labs will further accelerate this work by creating a powerful feedback loop between clinical biomarkers and continuous wearable data; by testing and tracking biomarkers, providing clinician-reviewed results, and delivering performance insights. This integration of blood testing, daily monitoring, and coaching drives actionable outcomes, ultimately helping members extend both their healthspan and quality of life, and bringing WHOOP closer to its mission of unlocking One Billion Healthy Years.

    PRESS KIT

    Launch assets, including images and product shots, are available here.

    About WHOOP

    WHOOP, the human performance company, empowers people to unlock their potential and live longer, healthier lives. The WHOOP membership delivers world-class wearable technology, personalized coaching, and actionable insights across recovery, sleep, training, and health. WHOOP wearable devices, including WHOOP 5.0 and WHOOP MG, feature groundbreaking innovations such as cardiovascular health screening (including an FDA-cleared ECG), Healthspan to measure Pace of Aging and WHOOP Age, and the first-of-its-kind wearable Blood Pressure Insights.

    Founded in 2012 and headquartered in Boston, WHOOP has raised more than $400 million in venture capital and ships to 56 markets worldwide. The WHOOP app is available in English, French, German, Italian, and Spanish. WHOOP is sold through leading retailers including Amazon in the U.S., U.K., and Australia, and the GCC; Best Buy and Dick's Sporting Goods in the U.S., Flipkart in India, and Virgin Megastore and Noon in the GCC.

    To learn more or start a one-month free trial, visit whoop.com and connect with WHOOP on Instagram, X, Facebook, LinkedIn, and YouTube.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250930178710/en/

    Taylor Georgeson

    Jack Taylor PR

    [email protected]

    Get the next $DGX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DGX

    DatePrice TargetRatingAnalyst
    8/25/2025$194.00Outperform → Neutral
    Robert W. Baird
    4/2/2025$195.00Buy
    Redburn Atlantic
    3/4/2025$185.00Buy → Neutral
    Citigroup
    1/6/2025$169.00 → $174.00Market Perform → Outperform
    Leerink Partners
    12/17/2024$145.00 → $172.00Equal-Weight → Overweight
    Morgan Stanley
    12/10/2024$175.00 → $185.00Buy
    Jefferies
    10/23/2024$157.00 → $182.00Neutral → Outperform
    Robert W. Baird
    8/28/2024$165.00In-line
    Evercore ISI
    More analyst ratings

    $DGX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    WHOOP Launches Clinician-Reviewed Advanced Labs, Unlocking a Comprehensive View of Human Health

    Over 350,000 members have joined the waitlist since May, underscoring the excitement for one product that can pair blood biomarkers with 24/7 wearable data WHOOP, the human performance company, today announced the launch of WHOOP Advanced Labs, a groundbreaking new feature that combines blood testing with continuous wearable data to deliver a complete picture of health. Members can upload past bloodwork results or schedule the company's curated Advanced Labs panel, which tests an extensive set of biomarkers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250930178710/en/WHOOP Launches Clinician-Reviewed Advanced Labs, Unlockin

    9/30/25 9:00:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics to Release Third Quarter 2025 Financial Results on October 21, 2025

    SECAUCUS, N.J., Sept. 25, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that it will report third quarter 2025 financial results on Tuesday, October 21, 2025, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast will be posted

    9/25/25 10:00:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant's Shield™ Blood-based Screening Test in the United States

    Collaboration to enable streamlined and accelerated access to Shield blood-based colorectal cancer screening test across Quest's vast network Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, and Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced a broad strategic collaboration to make Guardant's Shield™ blood-based screening test available to physicians and patients served by Quest in the United States. Shield is the first and only blood test to receive full FDA approval as a primary screening option for colorectal cancer in average-risk adults aged 45 and older. Through a multi-year agreement, Quest's provider clients that

    9/24/25 8:05:00 AM ET
    $DGX
    $GH
    Medical Specialities
    Health Care

    $DGX
    SEC Filings

    View All

    SEC Form 144 filed by Quest Diagnostics Incorporated

    144 - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    9/26/25 4:12:08 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form 144 filed by Quest Diagnostics Incorporated

    144 - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    9/23/25 4:14:25 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form 144 filed by Quest Diagnostics Incorporated

    144 - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    8/21/25 12:10:39 PM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP & General Counsel Prevoznik Michael E exercised 28,463 shares at a strike of $103.57 and sold $5,326,042 worth of shares (28,463 units at $187.12) (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    9/25/25 4:39:11 PM ET
    $DGX
    Medical Specialities
    Health Care

    SVP for Diagnostic Services Plewman Patrick sold $365,375 worth of shares (1,975 units at $185.00), decreasing direct ownership by 11% to 15,269 units (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    8/25/25 4:27:59 PM ET
    $DGX
    Medical Specialities
    Health Care

    SVP for Diagnostic Services Plewman Patrick exercised 4,532 shares at a strike of $112.17 and sold $829,356 worth of shares (4,532 units at $183.00) (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    8/21/25 4:34:05 PM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Quest Diagnostics downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Quest Diagnostics from Outperform to Neutral and set a new price target of $194.00

    8/25/25 8:10:20 AM ET
    $DGX
    Medical Specialities
    Health Care

    Redburn Atlantic initiated coverage on Quest Diagnostics with a new price target

    Redburn Atlantic initiated coverage of Quest Diagnostics with a rating of Buy and set a new price target of $195.00

    4/2/25 8:51:11 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics downgraded by Citigroup with a new price target

    Citigroup downgraded Quest Diagnostics from Buy to Neutral and set a new price target of $185.00

    3/4/25 7:20:57 AM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Financials

    Live finance-specific insights

    View All

    Quest Diagnostics to Release Third Quarter 2025 Financial Results on October 21, 2025

    SECAUCUS, N.J., Sept. 25, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that it will report third quarter 2025 financial results on Tuesday, October 21, 2025, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast will be posted

    9/25/25 10:00:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Declares Quarterly Cash Dividend

    SECAUCUS, N.J., Aug. 13, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on October 20, 2025 to shareholders of record of Quest Diagnostics common stock on October 3, 2025. About Quest DiagnosticsQuest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to ta

    8/13/25 6:35:00 PM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Reports Second Quarter 2025 Financial Results; Raises Guidance for Full Year 2025

    Second quarter revenues of $2.76 billion, up 15.2% from 2024Second quarter reported diluted earnings per share ("EPS") of $2.47, up 21.7% from 2024; and adjusted diluted EPS of $2.62, up 11.5% from 2024Year-to-date cash provided by operations of $858 million, up 67.1% from 2024Full year 2025 reported diluted EPS now expected to be between $8.60 and $8.80; and adjusted diluted EPS is expected to be between $9.63 and $9.83SECAUCUS, N.J., July 22, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced financial results for the second quarter ended June 30, 2025.

    7/22/25 6:47:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Leadership Updates

    Live Leadership Updates

    View All

    Fitbit and Quest Diagnostics Collaborate to Advance Research on the Use of Wearable Devices to Improve Metabolic Health

    Study to evaluate how behavioral and sensor data from wearables and blood tests can be leveraged to help individuals better assess and manage their metabolic health SECAUCUS, N.J., Jan. 17, 2024 /PRNewswire/ -- Fitbit and Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced a collaboration to study the potential of wearable devices to improve metabolic health, which influences risk of developing several diseases, including diabetes and heart disease. The Wearables for Metabolic Health (WEAR-ME) pilot study will pair beh

    1/17/24 8:58:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Board of Directors Elects James E. Davis Chairman of the Board

    SECAUCUS, N.J., March 3, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors elected James E. Davis, the company's Chief Executive Officer and President, to serve in the additional position of Chairman of the Board of Directors, effective April 1, 2023. "The Board carefully considered our governance structure and determined that combining the roles of Chairman and CEO under Jim Davis's leadership is in the best interest of shareholders to successfully continue to execute

    3/3/23 4:30:00 PM ET
    $DGX
    Medical Specialities
    Health Care

    Quotient Limited Announces Appointment of Chief Financial Officer

    JERSEY, Channel Islands, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced Ali Kiboro as the Company's Chief Financial Officer (CFO). Mr. Kiboro will assume the responsibilities of CFO on November 1st, 2021, replacing Mr. Peter Buhler who will support the Company during the transitional phase, as needed, before leaving Quotient Limited at year-end. "I am delighted to welcome Ali to the Executive team at this exciting time in our Company's evolution. He brings over 20 years of experience in global finance and has been a key driver of operational excellence in a career spanning healthcare services and manufacturing. I w

    10/12/21 8:45:00 AM ET
    $DGX
    $QTNT
    Medical Specialities
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    $DGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

    SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    2/13/24 5:12:21 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

    SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    1/25/24 12:16:40 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

    SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    2/7/23 1:25:52 PM ET
    $DGX
    Medical Specialities
    Health Care